Seikagaku Announces the Topline Results from a Phase III Clinical Study (Additional Study) in the U.S. for SI-6603, a Treatment for Lumbar Disc Herniation
Seikagaku Announces the Topline Results from a Phase III Clinical Study (Additional Study) in the U.S. for SI-6603, a Treatment for Lumbar Disc Herniation
05.26.2023
This link will direct you to a third-party site.(Another window opens.)
The Seikagaku Corporation website uses cookies to personalize contents and offer a better browsing experience. Please click the Accept botton. (Read more)